ClinicalTrials.gg
TerminatedNCT05403450Updated Oct 8, 2026

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

A Phase 1 interventional study of Tolinapant and Decitabine + Cedazuridine in Relapsed/Refractory Peripheral T-cell Lymphoma, sponsored by Taiho Oncology, Inc.. Terminated at 19 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Why this study was terminated
ASTX660-03 was closed according to protocol as no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria.

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.
Updated Oct 8, 2026No longer in United Kingdom27 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States — 21 open to participants now, 28 under way, 2 of them phase 3. Lymphoma, T-Cell, Peripheral · United States.

Enrollment
83rd of 157
33 · median 36
Started
2023
with 7 others
Phase 1
65 of 164
8 open now
Registered
144th of 164
by date

Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, this one is the 83rd largest by enrollment of the 157 interventional ones that give a count, is one of 8 that started in 2023, is one of 65 in phase 1, and was the 144th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

21 of the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.

As no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria, Sponsor decided to halt recruitment and to not conduct Phase 2 of the study.

03

Conditions studied

  • Relapsed/Refractory Peripheral T-cell Lymphoma

Keywords

  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with expected of >12 weeks.
  2. Participants must have confirmed R/R PTCL (local pathology report) as defined by 2016 World Health Organization (WHO) classification. The following subtypes are eligible for the study:

    1. Extranodal natural killer (NK)/T-cell lymphoma nasal type.
    2. Enteropathy-associated T-cell lymphoma.
    3. Monomorphic epitheliotropic intestinal T-cell lymphoma.
    4. Hepatosplenic T-cell lymphoma.
    5. Subcutaneous panniculitis-like T-cell lymphoma.
    6. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
    7. Angioimmunoblastic T-cell lymphoma.
    8. Follicular peripheral T-cell lymphoma.
    9. Nodal peripheral T-cell with T-follicular helper (THF) phenotype.
    10. Anaplastic large-cell lymphoma (ALCL).
  3. Participants must have evidence of progressive disease and must have received at least two prior systemic therapies.
  4. Participants must have by contrast-enhanced diagnostic CT (at least 1 nodal lesion >1.5 centimeters (cm) or extranodal lesions >1.0 cm).
  5. Participants with CD30-positive disease must have received, be ineligible for, or intolerant to brentuximab vedotin.
  6. (ECOG) performance status of 0, 1, or 2.
  7. Acceptable organ function as per protocol.
  8. Women of (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with tolinapant or any hypomethylating agent.
  2. to tolinapant or oral decitabine/cedazuridine, of the drug product, or other components of the study treatment regimen.
  3. Poor medical risk because of systemic diseases (e.g., uncontrolled infections) in addition to the qualifying disease under study.
  4. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise participant safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of tolinapant.
  5. A history of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:

    1. Abnormal .
    2. Congestive cardiac failure of Grade ≥3.
    3. Unstable cardiac disease.
    4. History or presence of complete left bundle branch block, third-degree heart block, cardiac pacemaker, or arrhythmia.
    5. History of long syndrome or ventricular arrhythmias including ventricular bigeminy.
    6. Screening 12-lead (ECG) with measurable QTc interval of ≥470 milliseconds (msec) (according to either Fridericia's or Bazett's correction).
    7. Any other condition that, in the opinion of the investigator, could put the participant at increased cardiac risk.
  6. Known history of (HIV) infection; or seropositive results consistent with active virus (HBV) or active virus (HCV) infection.
  7. Grade 3 or greater neuropathy.
  8. Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol treatment or assessments.
  9. Prior anticancer treatments or therapies within the indicated time window before first dose of study treatment (tolinapant), as follows:

    1. Cytotoxic chemotherapy or radiotherapy within 4 weeks prior.
    2. Monoclonal antibodies within 4 weeks prior.
    3. At least 12 weeks must have elapsed since chimeric antigen receptor T-cell (CAR-T) infusion.
    4. Small molecules or biologics ( or approved) within the longer of 3 weeks or 5 half-lives before study treatment.
  10. Monoclonal antibody treatment for rheumatologic conditions within 4 weeks of study drug initiation.
  11. Concurrent second currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy or superficial bladder cancer.
  12. Any concurrent second malignancy that is .
  13. Known central nervous system (CNS) lymphoma.
  14. Participants with a history of transplant are excluded from this study.
  15. Autotransplant within 100 days of the first dose of the study drug(s).
  16. Systemic >10 mg prednisone equivalent within 7 days of the first dose of study drug(s).
  17. Anti-T-cell directed therapy:

    1. Lymphotoxic agents (e.g., anti-CD52) in the past 12 months.
    2. Inhibitory drugs (e.g., calcineurin inhibitors) within 4 weeks of the first dose of study drug(s).
  18. Use of a concomitant medication which is a moderate or strong inhibitor/inducer within 2 weeks of the start of the study.
  19. Use of any vaccine within 10 days of the first dose of the study drug(s).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Phases 1 and 2: Tolinapant + Oral Decitabine/Cedazuridine

    Tolinapant, orally, once daily (QD) on Days 1 to 7 and 15 to 21 of each 28-day cycle in combination with oral decitabine/cedazuridine fixed-dose combination (FDC) tablet, QD on days determined by the Lead-in Phase during each 28-day cycle. The starting dose of tolinapant will be escalated stepwise in successive cohorts until the RP2D is determined. Based on RP2D and results determined from Phase 1 participants would receive tolinapant at the identified RP2D in combination with decitabine/cedazuridine, FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle in Phase 2.

    Drug: Tolinapant · Drug: Decitabine + Cedazuridine

  • Experimental
    Phase 1: Oral Decitabine/Cedazuridine

    Decitabine/cedazuridine FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle.

    Drug: Decitabine + Cedazuridine

Interventions

  • Capsule for oral administration

    Also known as: ASTX660

  • DrugDecitabine + Cedazuridine

    Drug pages: Decitabine · Cedazuridine

    Tablet for oral administration

    Also known as: ASTX727

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs)

    This will be evaluated by looking at the number of participants with treatment-related adverse events, serious adverse events (SAEs), and dose-limiting toxicities (DLTs), which are medical problems severe enough to stop study doctors from increasing a treatment dose.

    Time frame: Up to 54 months

  2. Phase 2: Antitumor Activity Assessed by Overall Response Rate (ORR) Based on 2014 Lugano Classification Using Computerized Tomography (CT) Imaging as the Primary Modality

    Time frame: Up to 54 months

Secondary outcomes

  1. Phase 1: Number of Participants With TEAEs, SAEs and DLTs in the Oral Decitabine/Cedazuridine Arm

    Time frame: Up to 54 months

  2. Ph 1 & 2: AUC: Area Under the Plasma Concentration-Time Curve

    Time frame: Up to 50 months

  3. Ph 1 & 2: Cmax: Maximum Observed Plasma Concentration

    Time frame: Up to 50 months

  4. Ph 1 & 2: Cmin: Minimum Observed Plasma Concentration at Steady State

    Time frame: Up to 50 months

  5. Ph 1 & 2: Tmax: Time to Maximum Observed Plasma Concentration

    Time frame: Up to 50 months

  6. Ph 1 & 2: t½: Apparent Elimination Half-Life

    Time frame: Up to 50 months

  7. Phase 2: Duration of response (DOR) Based on the Lugano Classification Using CT Imaging as the Primary Modality

    Time frame: Up to 54 months

  8. Phase 2: Percentage of Participants With Complete Response (CR) Based on the Lugano Classification Using CT Imaging as the Primary Modality

    Time frame: Up to 54 months

  9. Phase 2: Percentage of Participants With Partial Response (PR) Based on the Lugano Classification Using CT Imaging as the Primary Modality

    Time frame: Up to 54 months

  10. Phase 2: Progression-Free Survival (PFS) Based on the Lugano Classification Using CT Imaging as the Primary Modality

    Time frame: Up to 54 months

  11. Phase 2: Disease Control Rate (DCR) Assessed as Percentage of Participants With Disease Control Based on the Lugano Classification Using CT Imaging as the Primary Modality

    Time frame: Up to 54 months

  12. Phase 2: Overall Survival (OS) Based on the Lugano Classification Using CT Imaging as the Primary Modality

    Time frame: Up to 54 months

  13. Phase 2: Percentage of Participants With DOR, CR, PR, PFS, DCR,and OS Based on the Lugano Classification Using CT Along With PET Imaging Assessments

    Duration of response (DOR), complete response (CR), partial response (PR), progression-free survival (PFS), disease control rate (DCR)and overall survival (OS)

    Time frame: Up to 54 months

  14. Phase 2: Percentage of Participants With Anti-Tumor Activity Based on Assessment Using 2014 Lugano Classification With Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC)

    Anti-tumor activity in terms of ORR, DOR, CR, PR, and PFS will be evaluated based on assessment using 2014 Lugano Classification with LYRIC.

    Time frame: Up to 54 months

  15. Phase 2: Percentage of Participants With Anti-Tumor Activity Based on PTCL Subtypes Anti-tumor activity in terms of ORR, DOR, DCR, CR, and PR will be evaluated based on PTCL subtypes (using both pathology and molecular markers).

    Time frame: Up to 54 months

07

Study locations

19 sites
  • University of Colorado Anschutz Medical Campus Site #118
    Aurora, Colorado 80045, United States
  • Moffitt Cancer Center Site #157
    Tampa, Florida 33612, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • NYU Langone Laura and Isaac Perlmutter Cancer Center Site #153
    New York, New York 10016, United States
  • University of Pennsylvania Site# 160
    Philadelphia, Pennsylvania 19104, United States
  • The University of Texas MD Anderson Cancer Center Site #101
    Houston, Texas 77030, United States
  • Concord Hospital
    Concord, New South Wales 2139, Australia
  • Monash Medical Center
    Melbourne, Victoria 3168, Australia
  • Institut Bergonié Site#553
    Bordeaux, 33000, France
  • Institut Paoli-Calmettes
    Marseille, 13009, France
  • U.O.C. di Ematologia Pad. 8IRCCS Azienda OspedalieroUniversitaria di Bologna Site#651
    Bologna, 40138, Italy
  • Fondazione IRCCS San Gerardo dei Tintori Site #655
    Monza, 20900, Italy
  • Ośrodek Badań Klinicznych Wczesnych Faz - Uniwersyteckie Centrum Kliniczne w Gdańsku
    Gdansk, Pomeranian Voivodeship 80-214, Poland
  • Hospital Universitario Virgen del Rocío
    Seville, Andalusia 41013, Spain
  • Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
    Barcelona, Catalonia 8908, Spain
  • Hospital del Mar Site #704
    Barcelona, 08003, Spain
  • Hospital Universitario Fundación Jiménez Díaz Site #703
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre Site#710
    Madrid, 28041, Spain
  • Hospital Universitario Marqués de Valdecilla Site#711
    Santander, 39008, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Dec 2024, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
Jun 3, 2022
StartActual
Feb 22, 2023
Primary completionActual
Dec 16, 2024
CompletionActual
Jul 1, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
27 sites removed; no longer in United Kingdom
Show 27 removed
  • City of Hope Site #151 · Duarte, United States
  • University of Califonia, Los Angeles · Los Angeles, United States
  • Stanford University · Stanford, United States
  • Yale Cancer Center Site #109 · New Haven, United States
  • Johns Hopkins University · Baltimore, United States
  • University of Michigan Rogel Cancer Center · Ann Harbor, United States
  • Barbara Ann Karmanos Cancer Institute Site#159 · Detroit, United States
  • Rochester Skin Lymphoma Medical Group, PLLC Site #147 · Fairport, United States
  • University of Virginia Comprehensive Cancer Center · Charlottesville, United States
  • Fred Hutchinson Cancer Center · Seattle, United States
  • Linear Clinical Research Site #834 · Nedlands, Australia
  • Hôpital Bretonneau · Tours, France
  • Centre Henri Becquerel · Rouen, France
  • CHU Saint-Eloi Site#556 · Montpellier, France
  • Centre Antoine Lacassagne · Nice, France
  • AP-HP Pitie Saltpetriere Site# 552 · Paris, France
  • Institut Gustave Roussy · Villejuif, France
  • Ospedale Santa Maria delle Croci di Ravenna · Ravenna, Italy
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST · Meldola, Italy
  • Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia Site#650 · Brescia, Italy
  • Istituto Europeo di Oncologia Site#652 · Milan, Italy
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy · Warsaw, Poland
  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi · Lodz, Poland
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Guy's and Saint Thomas' NHS Foundation Trust · London, United Kingdom
  • University College London Hospitals NHS Foundation Trust · London, United Kingdom
  • The Christie NHS Foundation Trust · Manchester, United Kingdom
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    27 sites removed; no longer in United Kingdom
    Show 27 removed
    • City of Hope Site #151 · Duarte, United States
    • University of Califonia, Los Angeles · Los Angeles, United States
    • Stanford University · Stanford, United States
    • Yale Cancer Center Site #109 · New Haven, United States
    • Johns Hopkins University · Baltimore, United States
    • University of Michigan Rogel Cancer Center · Ann Harbor, United States
    • Barbara Ann Karmanos Cancer Institute Site#159 · Detroit, United States
    • Rochester Skin Lymphoma Medical Group, PLLC Site #147 · Fairport, United States
    • University of Virginia Comprehensive Cancer Center · Charlottesville, United States
    • Fred Hutchinson Cancer Center · Seattle, United States
    • Linear Clinical Research Site #834 · Nedlands, Australia
    • Hôpital Bretonneau · Tours, France
    • Centre Henri Becquerel · Rouen, France
    • CHU Saint-Eloi Site#556 · Montpellier, France
    • Centre Antoine Lacassagne · Nice, France
    • AP-HP Pitie Saltpetriere Site# 552 · Paris, France
    • Institut Gustave Roussy · Villejuif, France
    • Ospedale Santa Maria delle Croci di Ravenna · Ravenna, Italy
    • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST · Meldola, Italy
    • Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia Site#650 · Brescia, Italy
    • Istituto Europeo di Oncologia Site#652 · Milan, Italy
    • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy · Warsaw, Poland
    • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi · Lodz, Poland
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Guy's and Saint Thomas' NHS Foundation Trust · London, United Kingdom
    • University College London Hospitals NHS Foundation Trust · London, United Kingdom
    • The Christie NHS Foundation Trust · Manchester, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05403450
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Feb 22, 2023
Primary completion
Dec 16, 2024
Completion
Jul 1, 2026
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Decitabine · Cedazuridine

Start the discussion